Communiqués Avacta Group Plc

Actions

AVCT

GB00BYYW9G87

Recherche biotechnologique et médicale

Temps Différé London S.E. 13:59:05 04/09/2026			Varia. 5j.	Varia. 1 janv.
68,18 ^GBX	+3,30%		-0,04%	+17,54%

08:55	Avacta Group règle le paiement accéléré d'une obligation convertible amortissable	MT
09/07	Avacta nomme un nouveau vice-président " chevronné »	AN

Communiqués

23/07	Avacta : Research & Development Spotlight Series – Episode 15	PU
21/07	Avacta : Academy – Episode 4	PU
09/07	Avacta : Accelerated Amortized Payment of Convertible Bond Installment	PU
08/07	Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors	GL
25/06	Avacta : Announces U.S. FDA Agreement on Pivotal Trial Design for AVA6000 in Patients with Salivary Gland Cancer	PU
01/06	Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026	GL
01/06	Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026	AQ
29/05	Avacta : Annual Report and Accounts for the year ending 31 December 2025	PU
19/05	Unaudited Preliminary Results for the Year Ended December 31, 2025	GL
06/05	Avacta : presents new comparisons of pre\|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026	PU
06/05	Avacta presents new comparisons of pre\|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026	GL
21/04	Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre\|CISION® delivery platform	GL
14/04	Avacta CEO Christina Coughlin Named as One of In Vivo's 2026 Rising Leaders	GL
08/04	Avacta : Announces 2026 Science Day Event	PU
31/03	Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) - a sustained-release pre\|CISION® exatecan peptide drug conjugate	GL
27/03	Avacta : Results of Oversubscribed Placing and Subscription	PU
26/03	Avacta : Proposed Placing via an accelerated bookbuild and Subscription to raise approximately £10 million	PU
17/03	Avacta Announces Preclinical and Translational Presentations of pre\|CISION® Platform Candidates at the 2026 AACR Annual Conference	GL
04/03	Avacta : TD Cowen 46th Annual Healthcare Conference – Presentation slides	PU
04/03	Avacta : Corporate Deck – March 2026	PU
03/03	Avacta : Academy – Episode 2	PU
24/02	Avacta : Research & Development Spotlight Series, Episode 14	PU
24/02	Avacta's pre\|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis	GL
13/02	Avacta : Academy – Episode 1	PU
09/02	Avacta appoints Francis Wilson as Chief Scientific Officer	GL